AR018139A1 - Un compuesto n-[3-hidroxi-5[(1,4,5,6-tetrahidro-5-hidroxi-2-pirimidinil)amino]benzoil]glici-3-(3-halo-5-halo-2-hidroxifenil)-beta alanina, composicionfarmaceutica y uso del mismo en la fabricacion de un medicamento. - Google Patents

Un compuesto n-[3-hidroxi-5[(1,4,5,6-tetrahidro-5-hidroxi-2-pirimidinil)amino]benzoil]glici-3-(3-halo-5-halo-2-hidroxifenil)-beta alanina, composicionfarmaceutica y uso del mismo en la fabricacion de un medicamento.

Info

Publication number: AR018139A1
Authority: AR; Argentina
Prior art keywords: hidroxi; halo; manufacture; same; glici
Prior art date: 1998-03-04

Application number

ARP990100880A

Other languages

English (en)

Spanish (es)

Original Assignee

Searle & Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-03-04

Filing date

1999-03-02

Publication date

2001-10-31

1999-03-02 Application filed by Searle & Co filed Critical Searle & Co

2001-10-31 Publication of AR018139A1 publication Critical patent/AR018139A1/es

Links

150000001875 compounds Chemical class 0.000 title abstract 2
238000004519 manufacturing process Methods 0.000 title abstract 2
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 title 1
235000004279 alanine Nutrition 0.000 title 1
229940126601 medicinal product Drugs 0.000 title 1
125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
230000008485 antagonism Effects 0.000 abstract 1
229940079593 drug Drugs 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
125000005843 halogen group Chemical group 0.000 abstract 1
229910052739 hydrogen Inorganic materials 0.000 abstract 1
239000001257 hydrogen Substances 0.000 abstract 1
125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
230000005764 inhibitory process Effects 0.000 abstract 1
230000001404 mediated effect Effects 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
- C07D239/12—Nitrogen atoms not forming part of a nitro radical
- C07D239/14—Nitrogen atoms not forming part of a nitro radical with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to said nitrogen atoms

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Rheumatology (AREA)
Engineering & Computer Science (AREA)
Physical Education & Sports Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Orthopedic Medicine & Surgery (AREA)
Epidemiology (AREA)
Endocrinology (AREA)
Cardiology (AREA)
Hematology (AREA)
Obesity (AREA)
Pain & Pain Management (AREA)
Heart & Thoracic Surgery (AREA)
Oncology (AREA)
Diabetes (AREA)
Molecular Biology (AREA)
Immunology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Indole Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

ARP990100880A 1998-03-04 1999-03-02 Un compuesto n-[3-hidroxi-5[(1,4,5,6-tetrahidro-5-hidroxi-2-pirimidinil)amino]benzoil]glici-3-(3-halo-5-halo-2-hidroxifenil)-beta alanina, composicionfarmaceutica y uso del mismo en la fabricacion de un medicamento. AR018139A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US3427098A	1998-03-04	1998-03-04

Publications (1)

Publication Number	Publication Date
AR018139A1 true AR018139A1 (es)	2001-10-31

Family

ID=21875345

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ARP990100880A AR018139A1 (es)	1998-03-04	1999-03-02	Un compuesto n-[3-hidroxi-5[(1,4,5,6-tetrahidro-5-hidroxi-2-pirimidinil)amino]benzoil]glici-3-(3-halo-5-halo-2-hidroxifenil)-beta alanina, composicionfarmaceutica y uso del mismo en la fabricacion de un medicamento.

Country Status (29)

Country	Link
EP (1)	EP1060164A1 (fr)
JP (1)	JP2002505323A (fr)
KR (1)	KR20010041584A (fr)
CN (1)	CN1214011C (fr)
AP (1)	AP1244A (fr)
AR (1)	AR018139A1 (fr)
AU (1)	AU753230B2 (fr)
BG (1)	BG104740A (fr)
BR (1)	BR9908470A (fr)
CA (1)	CA2322207A1 (fr)
EA (1)	EA200000804A1 (fr)
EE (1)	EE200000506A (fr)
GE (1)	GEP20033118B (fr)
HR (1)	HRP20000574A2 (fr)
HU (1)	HUP0100865A3 (fr)
ID (1)	ID25591A (fr)
IL (1)	IL137653A0 (fr)
IS (1)	IS5582A (fr)
MY (1)	MY123908A (fr)
NO (1)	NO315703B1 (fr)
NZ (1)	NZ506598A (fr)
OA (1)	OA11530A (fr)
PL (1)	PL342726A1 (fr)
SK (1)	SK13002000A3 (fr)
TR (1)	TR200002542T2 (fr)
UA (1)	UA71906C2 (fr)
WO (1)	WO1999044994A1 (fr)
YU (1)	YU52000A (fr)
ZA (1)	ZA994406B (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9805655D0 (en)	1998-03-16	1998-05-13	Celltech Therapeutics Ltd	Chemical compounds
GB9814414D0 (en)	1998-07-03	1998-09-02	Celltech Therapeutics Ltd	Chemical compounds
GB9821061D0 (en)	1998-09-28	1998-11-18	Celltech Therapeutics Ltd	Chemical compounds
GB9826174D0 (en)	1998-11-30	1999-01-20	Celltech Therapeutics Ltd	Chemical compounds
US6518283B1 (en)	1999-05-28	2003-02-11	Celltech R&D Limited	Squaric acid derivatives
US6455539B2 (en)	1999-12-23	2002-09-24	Celltech R&D Limited	Squaric acid derivates
DE60130910T2 (de)	2000-04-17	2008-07-10	Ucb Pharma, S.A.	Enamin-derivate als zell-adhäsionsmoleküle
US6403608B1 (en)	2000-05-30	2002-06-11	Celltech R&D, Ltd.	3-Substituted isoquinolin-1-yl derivatives
US6545013B2 (en)	2000-05-30	2003-04-08	Celltech R&D Limited	2,7-naphthyridine derivatives
US6921767B2 (en) *	2000-06-15	2005-07-26	Pharmacia Corporation	Cycloalkyl alkanoic acids as integrin receptor antagonists derivatives
CA2417059A1 (fr)	2000-08-02	2002-02-07	Celltech R&D Limited	Derives d'isoquinoline-1-yl substitues en 3
EP1572210A1 (fr) *	2002-12-20	2005-09-14	Pharmacia Corporation	Isomere r de composes d'acides amines beta en tant que derives antagonistes du recepteur des integrines
UA87854C2 (en)	2004-06-07	2009-08-25	Мерк Энд Ко., Инк.	N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
AU2006257815A1 (en) *	2005-06-10	2006-12-21	Bipar Sciences, Inc.	PARP modulators and treatment of cancer
EP2131861A2 (fr)	2007-03-01	2009-12-16	Mallinckrodt Inc.	Petites molécules photoactives intégrées et leurs utilisations
JP4792124B1 (ja) *	2010-11-15	2011-10-12	エフイートレード株式会社	車両用保護フィルムの型取り方法、及び、車両用保護フィルムの製造方法
IN2015DN00099A (fr)	2012-07-18	2015-05-29	Univ Saint Louis
US8716226B2 (en)	2012-07-18	2014-05-06	Saint Louis University	3,5 phenyl-substituted beta amino acid derivatives as integrin antagonists
ES2864079T3 (es)	2014-05-30	2021-10-13	Pfizer	Derivados de carbonitrilo como moduladores selectivos del receptor de andrógenos
WO2015187774A1 (fr) *	2014-06-04	2015-12-10	Monsanto Technology Llc	Composés d'acide 3,6-dichlorosalicylique et procédés de synthèse associés
HK1244806A1 (zh)	2015-12-30	2018-08-17	Saint Louis University	作為過氧乙醯硝酸整聯蛋白拮抗劑的間氮雜環氨基苯甲酸衍生物
JP7661969B2 (ja)	2020-05-14	2025-04-15	Ｕｂｅ株式会社	１，４，５，６－テトラヒドロピリミジン－２－アミン誘導体
WO2023275715A1 (fr)	2021-06-30	2023-01-05	Pfizer Inc.	Métabolites de modulateurs sélectifs du récepteur des androgènes
JPWO2023085396A1 (fr)	2021-11-12	2023-05-19

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MX9801716A (es) *	1995-08-30	1998-05-31	Searle & Co	Derivados de meta-guanidina, urea, tiourea o acido aminobenzoico azaciclico, como antagonistas de integrina.

1999
- 1999-02-11 ZA ZA9904406A patent/ZA994406B/xx unknown
- 1999-02-22 SK SK1300-2000A patent/SK13002000A3/sk unknown
- 1999-02-22 PL PL99342726A patent/PL342726A1/xx unknown
- 1999-02-22 JP JP2000534538A patent/JP2002505323A/ja active Pending
- 1999-02-22 BR BR9908470-8A patent/BR9908470A/pt not_active Application Discontinuation
- 1999-02-22 EE EEP200000506A patent/EE200000506A/xx unknown
- 1999-02-22 ID IDW20001695A patent/ID25591A/id unknown
- 1999-02-22 CN CNB998035815A patent/CN1214011C/zh not_active Expired - Fee Related
- 1999-02-22 NZ NZ506598A patent/NZ506598A/en unknown
- 1999-02-22 YU YU52000A patent/YU52000A/sh unknown
- 1999-02-22 HU HU0100865A patent/HUP0100865A3/hu unknown
- 1999-02-22 AU AU32947/99A patent/AU753230B2/en not_active Ceased
- 1999-02-22 WO PCT/US1999/003281 patent/WO1999044994A1/fr not_active Ceased
- 1999-02-22 HR HR20000574A patent/HRP20000574A2/hr not_active Application Discontinuation
- 1999-02-22 UA UA2000095148A patent/UA71906C2/uk unknown
- 1999-02-22 EA EA200000804A patent/EA200000804A1/ru unknown
- 1999-02-22 GE GEAP19995537A patent/GEP20033118B/en unknown
- 1999-02-22 EP EP99937927A patent/EP1060164A1/fr active Pending
- 1999-02-22 CA CA002322207A patent/CA2322207A1/fr not_active Abandoned
- 1999-02-22 TR TR2000/02542T patent/TR200002542T2/xx unknown
- 1999-02-22 IL IL13765399A patent/IL137653A0/xx unknown
- 1999-02-22 OA OA1200000238A patent/OA11530A/en unknown
- 1999-02-22 AP APAP/P/2000/001893A patent/AP1244A/en active
- 1999-02-22 KR KR1020007009774A patent/KR20010041584A/ko not_active Ceased
- 1999-03-02 AR ARP990100880A patent/AR018139A1/es unknown
- 1999-03-03 MY MYPI99000772A patent/MY123908A/en unknown
2000
- 2000-08-04 IS IS5582A patent/IS5582A/is unknown
- 2000-08-30 NO NO20004316A patent/NO315703B1/no not_active IP Right Cessation
- 2000-09-01 BG BG104740A patent/BG104740A/xx unknown

Also Published As

Publication number	Publication date
BR9908470A (pt)	2000-12-05
ID25591A (id)	2000-10-19
TR200002542T2 (tr)	2001-05-21
MY123908A (en)	2006-06-30
PL342726A1 (en)	2001-07-02
NZ506598A (en)	2003-07-25
JP2002505323A (ja)	2002-02-19
NO20004316D0 (no)	2000-08-30
NO315703B1 (no)	2003-10-13
IS5582A (is)	2000-08-04
SK13002000A3 (sk)	2001-07-10
EE200000506A (et)	2002-04-15
AU3294799A (en)	1999-09-20
EP1060164A1 (fr)	2000-12-20
AP1244A (en)	2004-02-04
EA200000804A1 (ru)	2001-04-23
HUP0100865A3 (en)	2001-11-28
KR20010041584A (ko)	2001-05-25
ZA994406B (en)	2000-02-11
GEP20033118B (en)	2003-11-25
CA2322207A1 (fr)	1999-09-10
WO1999044994A1 (fr)	1999-09-10
YU52000A (sh)	2003-02-28
IL137653A0 (en)	2001-10-31
NO20004316L (no)	2000-11-06
CN1291978A (zh)	2001-04-18
OA11530A (en)	2004-05-17
CN1214011C (zh)	2005-08-10
HUP0100865A2 (hu)	2001-08-28
BG104740A (en)	2001-02-28
AU753230B2 (en)	2002-10-10
HRP20000574A2 (en)	2001-08-31
UA71906C2 (en)	2005-01-17
AP2000001893A0 (en)	2000-09-30

Similar Documents

Publication	Publication Date	Title
ECSP034732A (es)	2003-09-24	Derivado de fenetanolamina para el tratamiento de enfermedades respiratorias
PA8547701A1 (es)	2003-07-28	Nucleosidos 4 substituidos.
DE60330910D1 (de)	2010-02-25	Verbindungen mit selektiverinhibierender wirkung für gsk3
AR026173A1 (es)	2003-01-29	Inhibidores de neuraminidasas.
BR9908545A (pt)	2001-10-02	Derivado de piperidina, processo para a preparação do mesmo, composto, processo para a preparação do mesmo, e, composição farmacêutica
ES2058527T3 (es)	1994-11-01	Derivados de pirimidina condensados procedimiento y compuestos intermedios para su preparacion y composiciones farmaceuticas que los contienen.
AR009052A1 (es)	2000-03-08	Tienopirimidinas, un procedimiento para su preparacion, empleo de las mismas para preparar un medicamento, preparaciones farmaceuticas que lascontienen y un procedimiento para obtener estas preparaciones farmaceuticas
AR029403A1 (es)	2003-06-25	Derivados n-sustituidos de carbamoiloxialquil-azolio,un proceso para su fabricacion, composicion farmaceutica y el uso de los mismos para la preparacion de un medicamento
BRPI0406717A (pt)	2005-12-20	Composto, composição farmacêutica que compreende o mesmo, método de tratamento de uma enfermidade em um mamìfero, utilização do composto e processo para a sua produção
ES2083359T3 (es)	1996-04-16	Piperidinas 1,4-substituidas como inhibidores de la acetilcolinesterasa y su utilizacion en el tratamiento de la enfermedad de alzheimer.
AR035792A1 (es)	2004-07-14	Compuestos de n-(4-quinazolinil)-n-(1h-indazol-5-il) amina, inhibidor de la rho-quinasa, su uso para la fabricacion de un medicamento y metodo para prepararlo
BR0113234A (pt)	2004-02-25	Polimorfos de um análogo de epotilona
UY26872A1 (es)	2002-01-31	Derivados de la 4- fenil piridina
BRPI0409227B8 (pt)	2019-02-12	"composto, composição farmacêutica, uso de um composto e processo para a preparação de um composto de fórmula (i)"
AR008377A1 (es)	2000-01-19	Un compuesto derivado de la 3-aroilbencilpiridazinona, una composicion farmaceutica particularmente para el tratamiento de enfermedades inflamatorias o autoinmunes que contiene dicho compuesto
ES2158778B1 (es)	2002-03-16	Compuestos de sales de paroxetina, su preparacion y uso, y composiciones farmaceuticas que los contienen.
AR003440A1 (es)	1998-08-05	Nuevos derivados de aminoacidos, formulacion farmaceutica que los contiene, uso de dichos derivados para preparar medicamentos y procedimiento para la preparacion de dichos derivados.
BR0214243A (pt)	2004-12-21	Derivado de sulfonamida processo para a preparação de um derivado de sulfonamida e seus sais fisiologicamente aceitáveis, composição farmacêutica e uso de um derivado de sulfonamida
AR004961A1 (es)	1999-04-07	Modificacion cristalina v del clorhidrato de(r)-(-)-2-{n-[4-(1,1-dioxido-3- oxo-2,3-dihidro-benzisotiazol-2-il)-butil]-aminometil)cromano, unprocedimiento para su preparacion, medicamentos que lo contienen, el uso de dicho clorhidrato para la preparacion de medicamentos, una composicion para el
UY27700A1 (es)	2003-10-31	Compuestos oxo - azabiclícos.
UY27548A1 (es)	2003-06-30	Sales de ácido succínico de 5,7,14-triazatetraciclo (10.3.1.02.11.04,9) exadeca-2 (11),3,5,7,9-pentaeno y composiciones farmacéuticas
AR013079A1 (es)	2000-12-13	Derivados sustituidos de tetrahidrofurano-3-onas, de tetrahidropirano-3- onas y tetrahidrotiofen-3-onas, un procedimiento para su preparacion unacomposicion farmaceutica de un medicamento util como inhibidores de proteasas e intermediarios
BR0207408A (pt)	2004-02-25	Azóis como inibidores de malonil-coa decarboxilase úteis como moduladores metabólicos
ES2038172T3 (es)	1993-07-16	Procedimiento para preparar carboxamidas heterociclicas.
BRPI0416287A (pt)	2007-01-23	compostos, processo para a manufatura dos mesmos, composições farmacêuticas que os compreendem, método para o tratamento e/ou prevenção de enfermidades que são moduladas por inibidores de accß e sua utilização

Legal Events

Date	Code	Title	Description
2007-10-19	FB	Suspension of granting procedure